

Julius Popp

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2426964/julius-popp-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

119
papers

3,997
citations

32
h-index

60
g-index

155
ext. papers

5,583
ext. citations

5.6
avg. IF

5.13
L-index

#	Paper	IF	Citations
119	Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 1924-38	27.4	842
118	Glucose metabolism, gray matter structure, and memory decline in subjective memory impairment. <i>Neurology</i> , 2012 , 79, 1332-9	6.5	207
117	Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. <i>Lancet Neurology</i> , 2013 , 12, 233-43	24.1	146
116	Validity and reliability of the CAM-ICU Flowsheet to diagnose delirium in surgical ICU patients. <i>Journal of Critical Care</i> , 2010 , 25, 144-51	4	132
115	Volume loss of the medial temporal lobe structures in subjective memory impairment. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010 , 29, 75-81	2.6	118
114	High Cortisol and the Risk of Dementia and Alzheimer's Disease: A Review of the Literature. <i>Frontiers in Aging Neuroscience</i> , 2019 , 11, 43	5.3	104
113	Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type. <i>Neurobiology of Aging</i> , 2015 , 36, 601-7	5.6	99
112	Association of Cerebral Amyloid- β Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018 , 75, 84-95	14.5	94
111	CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study. <i>Alzheimer's and Dementia</i> , 2015 , 11, 1306-15	1.2	87
110	Blood-brain barrier breakdown, neuroinflammation, and cognitive decline in older adults. <i>Alzheimer's and Dementia</i> , 2018 , 14, 1640-1650	1.2	87
109	Inflammatory biomarkers in Alzheimer's disease plasma. <i>Alzheimer's and Dementia</i> , 2019 , 15, 776-787	1.2	74
108	Cerebral and extracerebral cholesterol metabolism and CSF markers of Alzheimer's disease. <i>Biochemical Pharmacology</i> , 2013 , 86, 37-42	6	69
107	Predisposing and precipitating factors of delirium after cardiac surgery: a prospective observational cohort study. <i>Annals of Surgery</i> , 2013 , 257, 1160-7	7.8	64
106	S-adenosylmethionine is decreased in the cerebrospinal fluid of patients with Alzheimer's disease. <i>Neurodegenerative Diseases</i> , 2010 , 7, 373-8	2.3	64
105	Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults. <i>Brain, Behavior, and Immunity</i> , 2017 , 62, 203-211	16.6	63
104	Sleep characteristics and cognitive impairment in the general population: The HypnoLaus study. <i>Neurology</i> , 2017 , 88, 463-469	6.5	63
103	The role of macrophage migration inhibitory factor in Alzheimer's disease. <i>Molecular Medicine</i> , 2010 , 16, 116-21	6.2	61

102	Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum. <i>Alzheimer's and Dementia</i> , 2019 , 15, 644-654	1.2	57
101	Macrophage migration inhibitory factor in mild cognitive impairment and Alzheimer's disease. <i>Journal of Psychiatric Research</i> , 2009 , 43, 749-53	5.2	57
100	CSF cortisol in Alzheimer's disease and mild cognitive impairment. <i>Neurobiology of Aging</i> , 2009 , 30, 498-500	5.0	57
99	Systemic and central nervous system metabolic alterations in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019 , 11, 93	9	57
98	Cholesterol metabolism is associated with soluble amyloid precursor protein production in Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2012 , 123, 310-6	6	51
97	Homocysteine metabolism and cerebrospinal fluid markers for Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2009 , 18, 819-28	4.3	43
96	Alterations of cholesterol precursor levels in Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2010 , 1801, 945-50	5	42
95	Cerebrospinal fluid soluble amyloid- β protein precursor as a potential novel biomarkers of Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2012 , 28, 119-25	4.3	38
94	Implications of objective vs subjective delirium assessment in surgical intensive care patients. <i>American Journal of Critical Care</i> , 2012 , 21, e12-20	1.7	38
93	Prevalence of the apolipoprotein E $\epsilon 4$ allele in amyloid β positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018 , 14, 913-924	1.2	36
92	Delirium in the elderly: Current problems with increasing geriatric age. <i>Indian Journal of Medical Research</i> , 2015 , 142, 655-62	2.9	35
91	A global HILIC-MS approach to measure polar human cerebrospinal fluid metabolome: Exploring gender-associated variation in a cohort of elderly cognitively healthy subjects. <i>Analytica Chimica Acta</i> , 2018 , 1037, 327-337	6.6	34
90	Alzheimer disease pathology and the cerebrospinal fluid proteome. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 66	9	34
89	Cholesterol synthesis, cholesterol absorption, and mortality in hemodialysis patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012 , 7, 943-8	6.9	34
88	Cerebrospinal fluid markers for Alzheimer's disease over the lifespan: effects of age and the APOE $\epsilon 4$ genotype. <i>Journal of Alzheimer's Disease</i> , 2010 , 22, 459-68	4.3	33
87	ICP-MS/MS-Based Ionomics: A Validated Methodology to Investigate the Biological Variability of the Human Ionome. <i>Journal of Proteome Research</i> , 2017 , 16, 2080-2090	5.6	32
86	The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 64	9	31
85	SUCLG2 identified as both a determinant of CSF A β -42 levels and an attenuator of cognitive decline in Alzheimer's disease. <i>Human Molecular Genetics</i> , 2014 , 23, 6644-58	5.6	30

84	MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 100	9	30
83	CYP46A1 variants influence Alzheimer's disease risk and brain cholesterol metabolism. <i>European Psychiatry</i> , 2009 , 24, 183-90	6	29
82	A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019 , 5, 933-938	6	29
81	New insights into the genetic etiology of Alzheimer's disease and related dementias.. <i>Nature Genetics</i> , 2022 ,	36.3	27
80	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. <i>Alzheimer's and Dementia</i> , 2019 , 15, 817-827	1.2	26
79	Mechanical ventilation in ischemic stroke. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2004 , 13, 183-8.8	2.8	26
78	One-carbon metabolism, cognitive impairment and CSF measures of Alzheimer pathology: homocysteine and beyond. <i>Alzheimer's Research and Therapy</i> , 2017 , 9, 43	9	25
77	Subjective cognitive decline in patients with mild cognitive impairment and healthy older adults: association with personality traits. <i>Geriatrics and Gerontology International</i> , 2014 , 14, 589-95	2.9	25
76	New insights on the genetic etiology of Alzheimer's and related dementia		25
75	Life events, salivary cortisol, and cognitive performance in nondemented subjects: a population-based study. <i>Neurobiology of Aging</i> , 2017 , 51, 1-8	5.6	24
74	Dimethylarginines, homocysteine metabolism, and cerebrospinal fluid markers for Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2012 , 31, 751-8	4.3	24
73	RXRA gene variations influence Alzheimer's disease risk and cholesterol metabolism. <i>Journal of Cellular and Molecular Medicine</i> , 2009 , 13, 589-98	5.6	24
72	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021 , 12, 3417	17.4	23
71	Macrophage Migration Inhibitory Factor is Associated with Biomarkers of Alzheimer's Disease Pathology and Predicts Cognitive Decline in Mild Cognitive Impairment and Mild Dementia. <i>Journal of Alzheimer's Disease</i> , 2017 , 60, 273-281	4.3	22
70	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. <i>Alzheimer's and Dementia</i> , 2019 , 15, 1478-1488	1.2	22
69	Personality, Cortisol, and Cognition in Non-demented Elderly Subjects: Results from a Population-Based Study. <i>Frontiers in Aging Neuroscience</i> , 2017 , 9, 63	5.3	21
68	CETP polymorphisms influence cholesterol metabolism but not Alzheimer's disease risk. <i>Brain Research</i> , 2008 , 1232, 1-6	3.7	21
67	Neuroticism, depression, and anxiety traits exacerbate the state of cognitive impairment and hippocampal vulnerability to Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017 , 7, 107-114	5.2	19

66	Determinants of the essential one-carbon metabolism metabolites, homocysteine, S-adenosylmethionine, S-adenosylhomocysteine and folate, in cerebrospinal fluid. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012 , 50, 1641-7	5.9	19
65	Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization. <i>Journal of Alzheimers Disease</i> , 2017 , 55, 159-170	4.3	19
64	PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment. <i>Acta Neuropathologica</i> , 2020 , 139, 1025-1044	14.3	18
63	Pharmacological treatment of dementia and mild cognitive impairment due to Alzheimer's disease. <i>Current Opinion in Psychiatry</i> , 2011 , 24, 556-61	4.9	18
62	Prevention and treatment options for postoperative delirium in the elderly. <i>Current Opinion in Psychiatry</i> , 2012 , 25, 515-21	4.9	18
61	Homocysteine metabolism is associated with cerebrospinal fluid levels of soluble amyloid precursor protein and amyloid beta. <i>Journal of Neurochemistry</i> , 2016 , 139, 324-332	6	18
60	Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia. <i>Experimental Gerontology</i> , 2017 , 100, 45-53	4.5	17
59	Behavioral and psychological symptoms and cognitive decline in patients with amnesic MCI and mild AD: a two-year follow-up study. <i>International Psychogeriatrics</i> , 2015 , 27, 1379-89	3.4	16
58	Differentially expressed gene profile in the 6-hydroxy-dopamine-induced cell culture model of Parkinson's disease. <i>Neuroscience Letters</i> , 2012 , 507, 10-5	3.3	16
57	Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics. <i>Brain</i> , 2020 , 143, 3776-3792	11.2	16
56	Interaction between personality traits and cerebrospinal fluid biomarkers of Alzheimer's disease pathology modulates cognitive performance. <i>Alzheimers Research and Therapy</i> , 2017 , 9, 6	9	15
55	Proteomes of Paired Human Cerebrospinal Fluid and Plasma: Relation to Blood-Brain Barrier Permeability in Older Adults. <i>Journal of Proteome Research</i> , 2019 , 18, 1162-1174	5.6	15
54	Measurement of ERK 1/2 in CSF from patients with neuropsychiatric disorders and evidence for the presence of the activated form. <i>Journal of Alzheimers Disease</i> , 2009 , 18, 613-22	4.3	14
53	APOE ϵ genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease. <i>Alzheimers Research and Therapy</i> , 2020 , 12, 65	9	13
52	Plasma Proteomic Profiles of Cerebrospinal Fluid-Defined Alzheimer's Disease Pathology in Older Adults. <i>Journal of Alzheimers Disease</i> , 2017 , 60, 1641-1652	4.3	13
51	Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression. <i>Alzheimers Research and Therapy</i> , 2021 , 13, 65	9	13
50	Delirium and cognitive decline: more than a coincidence. <i>Current Opinion in Neurology</i> , 2013 , 26, 634-9	7.1	11
49	An integrative multi-omics approach reveals new central nervous system pathway alterations in Alzheimer's disease. <i>Alzheimers Research and Therapy</i> , 2021 , 13, 71	9	11

48	Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. <i>Journal of Alzheimer's Disease</i> , 2020 , 74, 213-225	4.3	10
47	Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. <i>Translational Psychiatry</i> , 2020 , 10, 403	8.6	10
46	Key role of MIF-related neuroinflammation in neurodegeneration and cognitive impairment in Alzheimer's disease. <i>Molecular Medicine</i> , 2020 , 26, 34	6.2	10
45	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.. <i>JAMA Neurology</i> , 2022 ,	17.2	9
44	Association of N-acetylaspartate and cerebrospinal fluid A β 2 in dementia. <i>Journal of Alzheimer's Disease</i> , 2011 , 27, 393-9	4.3	8
43	Preoperative Depression and Plasma Cortisol Levels as Predictors of Delirium after Cardiac Surgery. <i>Dementia and Geriatric Cognitive Disorders</i> , 2019 , 48, 207-214	2.6	8
42	Factors associated with subjective cognitive decline in dementia-free older adults-A population-based study. <i>International Journal of Geriatric Psychiatry</i> , 2021 , 36, 1188-1196	3.9	8
41	Early-Stage Alzheimer's Disease Does Not Alter Pupil Responses to Colored Light Stimuli. <i>Journal of Alzheimer's Disease</i> , 2020 , 75, 1273-1282	4.3	5
40	Plasma homocysteine and cerebrospinal fluid neurodegeneration biomarkers in mild cognitive impairment and dementia. <i>Journal of the American Geriatrics Society</i> , 2009 , 57, 737-9	5.6	4
39	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. <i>Journal of Alzheimer's Disease</i> , 2020 , 77, 1353-1368	4.3	4
38	Replication study of plasma proteins relating to Alzheimer's pathology. <i>Alzheimer's and Dementia</i> , 2021 , 17, 1452-1464	1.2	4
37	TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. <i>Alzheimer's and Dementia</i> , 2021 , 17, 1628-1640	1.2	4
36	The power of personality in successful ageing: a comprehensive review of larger quantitative studies. <i>European Journal of Ageing</i> , 2021 , 18, 269-285	3.6	4
35	Cholesterol metabolites and plant sterols in cerebrospinal fluid are associated with Alzheimer's cerebral pathology and clinical disease progression. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2021 , 205, 105785	5.1	4
34	The Effects of Hand Massage on Stress and Agitation Among People with Dementia in a Hospital Setting: A Pilot Study. <i>Applied Psychophysiology Biofeedback</i> , 2018 , 43, 319-332	3.4	4
33	Preoperative Cognitive Impairment and Postoperative Delirium Predict Decline in Activities of Daily Living after Cardiac Surgery-A Prospective, Observational Cohort Study. <i>Geriatrics (Switzerland)</i> , 2020 , 5,	2.2	3
32	Plasma Proteomic Biomarkers Relating to Alzheimer's Disease: A Meta-Analysis Based on Our Own Studies. <i>Frontiers in Aging Neuroscience</i> , 2021 , 13, 712545	5.3	3
31	P2-147: A Neuroinflammatory Biomarker Signature of Blood-Brain Barrier Impairment in Older Adults 2016 , 12, P670-P670		2

30	LC-HRMS data as a result of untargeted metabolomic profiling of human cerebrospinal fluid. <i>Data in Brief</i> , 2018 , 21, 1358-1362	1.2	2
29	Do diurnal cortisol levels mediate the association between sleep disturbances and cognitive impairment?. <i>Neurobiology of Aging</i> , 2018 , 69, 65-67	5.6	2
28	CSF Proteomic Alzheimer's Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals. <i>Proteomes</i> , 2021 , 9,	4.6	2
27	Identification of plasma proteome signatures associated with ATN framework using SOMAscan. <i>Alzheimer's and Dementia</i> , 2020 , 16, e036954	1.2	1
26	CSF proteomic profiling of mild cognitive impairment individuals with suspected non-Alzheimer's disease pathophysiology. <i>Alzheimer's and Dementia</i> , 2020 , 16, e047247	1.2	1
25	Salivary cortisol and five-year change in cognitive performance in non-demented elderly subjects: a population-based study. <i>Neurobiology of Aging</i> , 2020 , 94, 34-37	5.6	1
24	Histologically confirmed amyloid deposition and low CSF Abeta42 in a cognitively normal subject. <i>Journal of Neurology</i> , 2007 , 254, 970-1	5.5	1
23	Cerebrospinal fluid total tau levels indicate aberrant neuronal plasticity in Alzheimer's disease 2020 ,		1
22	Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset		1
21	P2-608: SALIVARY CORTISOL AND 5Y CHANGE IN COGNITIVE FUNCTION IN COMMUNITY DWELLING, COGNITIVELY HEALTHY OLDER ADULTS: THE PSYCOLAUS COHORT STUDY 2018 , 14, P972-P972		1
20	Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease.. <i>Molecular Neurodegeneration</i> , 2022 , 17, 27	19	1
19	Genome-Wide Association Study of Alzheimer's Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery Dataset.. <i>Frontiers in Aging Neuroscience</i> , 2022 , 14, 840651	5.3	0
18	An integrative, hypothesis-free, multi-omics approach uncovers biological pathway alterations in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020 , 16, e038563	1.2	
17	Determinants of subjective cognitive decline in dementia-free older adults: A population-based study. <i>Alzheimer's and Dementia</i> , 2020 , 16, e038805	1.2	
16	Neurofilament light and cognitive performance: Associations with amyloid and vascular pathologies in individuals with mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2020 , 16, e042739	1.2	
15	DNA methylation differences associated with peripheral biomarkers in the EMIF-AD cohort. <i>Alzheimer's and Dementia</i> , 2020 , 16, e045853	1.2	
14	Synaptic proteins relate to memory scores in preclinical Alzheimer's disease and cognitively healthy controls depending on amyloid. <i>Alzheimer's and Dementia</i> , 2020 , 16, e046102	1.2	
13	Response to a letter to the editor: sleep disturbance as a stressor event in elderly's life. <i>Neurobiology of Aging</i> , 2017 , 60, 204	5.6	

12 P4-525: ASSOCIATION OF CSF TAU WITH HYPERPLASTICITY IN ALZHEIMER'S DISEASE **2019**, 15, P1515-P1516

11 ASSOCIATIONS BETWEEN CEREBROSPINAL FLUID NEURODEGENERATIVE MARKERS, NEUROFILAMENT-LIGHT AND TOTAL TAU AND CEREBROVASCULAR IMAGING MARKERS **2019**, 15, P1626-P1627

10 P3-418: INTEGRATIVE PREDICTION OF COGNITIVE DECLINE USING ATROPHY NETWORKS, CSF BIOMARKERS, AND GENOTYPE DATA **2018**, 14, P1267-P1267

9 P2-270: INCREASED CSF AMYLOID- β -38 AND 1-40 CONCENTRATIONS IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT WITH TAU BUT WITHOUT AMYLOID PATHOPHYSIOLOGY **2018**, 14, P780-P781

8 P3-233: PLASMA PRIMARY FATTY AMIDES ASSOCIATE TO CSF AMYLOID LEVELS AND ALZHEIMER'S DISEASE PROGRESSION IN THE EMIF-AD BIOMARKER DISCOVERY COHORT **2018**, 14, P1161-P1161

7 F1-02-04: GENOMICS AND EPIGENOMICS ANALYSES IN THE EMIF-AD MULTIMODAL BIOMARKER DISCOVERY STUDY **2018**, 14, P204-P204

6 F1-02-02: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN AND ALZHEIMER'S DISEASE PROGRESSION **2018**, 14, P201-P202

5 F1-02-01: RELATING CSF MARKERS NEUROGRANIN, NEUROFILAMENT-LIGHT AND YKL-40 TO A β APOE ϵ AND COGNITION: RESULTS FROM THE EMIF-AD MULTIMODAL BIOMARKER DISCOVERY STUDY **2018**, 14, P201-P201

4 P4-193: IDENTIFICATION AND COMPREHENSIVE CHARACTERIZATION OF CNS AND SYSTEMIC METABOLIC ALTERATIONS IN ALZHEIMER'S DISEASE **2018**, 14, P1513-P1514

3 P2-458: PREDICTING COGNITIVE DECLINE THROUGH STRUCTURAL MRI BIOMARKERS: RESULTS FROM THE EMIF-AD BIOMARKER DISCOVERY STUDY **2018**, 14, P895-P896

2 F1-02-03: MRI PREDICTORS OF AMYLOID PATHOLOGY: RESULTS FROM THE EMIF-AD BIOMARKER DISCOVERY STUDY **2018**, 14, P202-P204

1 Effects of age, amyloid, sex, and β on the CSF proteome in normal cognition.. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2022**, 14, e12286

5-2